Novartis shares tumble after del-desiran trial fails, worst day in 20+ years
Novartis (NVS) shares slid 14% after a late-stage study of del-desiran in myotonic dystrophy type 1 failed its primary test, the second failed trial in a week.
Novartis shares (NVS) sold off hard on Tuesday after the company said a late-stage study of del-desiran in myotonic dystrophy type 1 failed its primary test, marking its second failed trial in a week. The stock closed down 14%, clocking its worst day in over 20 years. Hand-Stiffness Test Falls ShortT…